<DOC>
	<DOCNO>NCT03006068</DOCNO>
	<brief_summary>This study design evaluate long-term safety efficacy ABT-494 participant ulcerative colitis ( UC ) respond end induction period Study M14-234 ( Substudies 1 2 ) , loss response maintenance period Study M14-234 ( Substudy 3 ) , successfully complete Study M14-234 .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Safety Efficacy ABT-494 Subjects With Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Participant achieve clinical response end induction period ( Week 8 ) Study M14234 ( Substudies 1 2 ) , loss response maintenance period Study M14234 ( Substudy 3 ) , successfully complete Study M14234 . If female , participant must meet criterion Contraception Recommendations Pregnancy Testing . Male participant must agree follow protocolspecified pregnancy avoidance measure , include refrain donate sperm , 90 day post last dose study drug . Participant judge otherwise good health determine principal investigator base upon clinical evaluation perform precede study ( Study M14234 ) . Must able willing give write informed consent comply requirement study protocol . For reason participant consider investigator unsuitable candidate . Female participant positive pregnancy test Baseline ( final visit Study M14234 ) consider become pregnant study . Participant active recurrent infection base investigator 's clinical assessment make participant unsuitable candidate study . Participants ongoing infection undergo treatment may enrol BUT NOT dose infection successfully treat . Current evidence active untreated latent tuberculosis . Participant poorly control medical condition , uncontrolled diabetes , unstable ischemic heart disease , moderate severe congestive heart failure , recent cerebrovascular accident condition , opinion investigator sponsor , would put subject risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Open-Label Extension ( OLE )</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Ulcerative Colitis ( UC )</keyword>
	<keyword>ABT-494</keyword>
	<keyword>Safety</keyword>
</DOC>